FR3103701B1 - Composés de typen2-arylméthyl-4-haloalkyl-pyridazin-3-one et leur utilisation - Google Patents
Composés de typen2-arylméthyl-4-haloalkyl-pyridazin-3-one et leur utilisation Download PDFInfo
- Publication number
- FR3103701B1 FR3103701B1 FR1913404A FR1913404A FR3103701B1 FR 3103701 B1 FR3103701 B1 FR 3103701B1 FR 1913404 A FR1913404 A FR 1913404A FR 1913404 A FR1913404 A FR 1913404A FR 3103701 B1 FR3103701 B1 FR 3103701B1
- Authority
- FR
- France
- Prior art keywords
- compounds
- typen2
- arylmethyl
- pyridazin
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1913404A FR3103701B1 (fr) | 2019-11-28 | 2019-11-28 | Composés de typen2-arylméthyl-4-haloalkyl-pyridazin-3-one et leur utilisation |
| PCT/FR2020/052228 WO2021105641A1 (fr) | 2019-11-28 | 2020-11-30 | Modulateurs de cftr de type n2-arylmethyl-4-haloalkyl-pyridazin-3-one pour le traitement de la mucoviscidose |
| EP20828531.2A EP4065120A1 (fr) | 2019-11-28 | 2020-11-30 | Modulateurs de cftr de type n2-arylmethyl-4-haloalkyl-pyridazin-3-one pour le traitement de la mucoviscidose |
| US17/780,148 US20230013304A1 (en) | 2019-11-28 | 2020-11-30 | N2-arylmethyl-4-haloalkyl-pyridazin-3-one cftr modulators for the treatment of cystic fibrosis |
| CA3163176A CA3163176A1 (fr) | 2019-11-28 | 2020-11-30 | Modulateurs de cftr de type n2-arylmethyl-4-haloalkyl-pyridazin-3-one pour le traitement de la mucoviscidose |
| CN202080092401.8A CN114945368A (zh) | 2019-11-28 | 2020-11-30 | N2-芳基甲基-4-卤代烷基-哒嗪-3-酮化合物及其用途 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1913404A FR3103701B1 (fr) | 2019-11-28 | 2019-11-28 | Composés de typen2-arylméthyl-4-haloalkyl-pyridazin-3-one et leur utilisation |
| FR1913404 | 2019-11-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR3103701A1 FR3103701A1 (fr) | 2021-06-04 |
| FR3103701B1 true FR3103701B1 (fr) | 2021-11-26 |
Family
ID=70295227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR1913404A Active FR3103701B1 (fr) | 2019-11-28 | 2019-11-28 | Composés de typen2-arylméthyl-4-haloalkyl-pyridazin-3-one et leur utilisation |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230013304A1 (zh) |
| EP (1) | EP4065120A1 (zh) |
| CN (1) | CN114945368A (zh) |
| CA (1) | CA3163176A1 (zh) |
| FR (1) | FR3103701B1 (zh) |
| WO (1) | WO2021105641A1 (zh) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000247959A (ja) * | 1999-02-26 | 2000-09-12 | Kowa Co | ピリダジン−３−オン誘導体及びこれを含有する医薬 |
| CN1759103A (zh) * | 2003-03-18 | 2006-04-12 | 兴和株式会社 | 水溶性苯基哒嗪衍生物及含有该衍生物的医药品 |
| WO2008121877A2 (en) * | 2007-04-02 | 2008-10-09 | Institute For Oneworld Health | Cftr inhibitor compounds and uses thereof |
| BR112015023328A2 (pt) | 2013-03-13 | 2017-07-18 | Flatley Discovery Lab | compostos de piridazinona e métodos para o tratamento de fibrose cística |
| FR3027901B1 (fr) | 2014-10-31 | 2018-03-16 | Universite De Reims Champagne Ardenne | Nouveaux procedes appartenant a la famille des pyridazinones. |
| EP3532467A1 (en) * | 2016-10-26 | 2019-09-04 | Proteostasis Therapeutics, Inc. | Pyridazine derivatives, compositions and methods for modulating cftr |
-
2019
- 2019-11-28 FR FR1913404A patent/FR3103701B1/fr active Active
-
2020
- 2020-11-30 EP EP20828531.2A patent/EP4065120A1/fr active Pending
- 2020-11-30 CN CN202080092401.8A patent/CN114945368A/zh active Pending
- 2020-11-30 WO PCT/FR2020/052228 patent/WO2021105641A1/fr unknown
- 2020-11-30 CA CA3163176A patent/CA3163176A1/fr active Pending
- 2020-11-30 US US17/780,148 patent/US20230013304A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021105641A1 (fr) | 2021-06-03 |
| CN114945368A (zh) | 2022-08-26 |
| CA3163176A1 (fr) | 2021-06-03 |
| US20230013304A1 (en) | 2023-01-19 |
| EP4065120A1 (fr) | 2022-10-05 |
| FR3103701A1 (fr) | 2021-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46018A (fr) | Activateurs d'édition du génome | |
| MA44674A (fr) | Inhibiteurs de bromodomaine | |
| MA40240B1 (fr) | Composés hétéroaryle d'inhibition de la kinase | |
| EA202092490A1 (ru) | Модуляторы метилмодифицирующих ферментов, композиции и их применения | |
| MA47447A (fr) | 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer | |
| MA33552B1 (fr) | Énantiomères de composés de spiro-oxindole et leurs utilisations en tant qu'agents thérapeutiques | |
| MX2022016463A (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. | |
| MA54227B1 (fr) | Méthodes de traitement de la fibrose kystique | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| PH12021550882A1 (en) | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders | |
| TN2010000230A1 (fr) | Agonistes nouveaux des recepteurs de glucocorticoides | |
| EA201490277A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| MA54386B1 (fr) | Modulateurs de trex1 | |
| MA50013B1 (fr) | Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton | |
| MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
| WO2020212760A3 (en) | Compounds and methods for the treatment of ocular disorders | |
| EA202191170A1 (ru) | Комбинированная терапия для лечения гематологических заболеваний | |
| FR3065642B1 (fr) | Utilisation de 20-hydroxyecdysone et ses derives dans le traitement des myopathies | |
| EA202092719A1 (ru) | Бензолсульфонамидные соединения и их применение в качестве терапевтических средств | |
| CR20220280A (es) | Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2 | |
| MA49839B1 (fr) | Inhibiteurs bicycliques de la histone déacétylase | |
| FR3084254B1 (fr) | Derives deuteres du lanifibranor | |
| MX2023004537A (es) | Compuestos y metodos para el tratamiento de trastornos oculares. | |
| FR3103701B1 (fr) | Composés de typen2-arylméthyl-4-haloalkyl-pyridazin-3-one et leur utilisation | |
| MA53372B1 (fr) | Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PLFP | Fee payment |
Year of fee payment: 2 |
|
| PLSC | Publication of the preliminary search report |
Effective date: 20210604 |
|
| PLFP | Fee payment |
Year of fee payment: 3 |
|
| TQ | Partial transmission of property |
Owner name: INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE R, FR Effective date: 20220613 Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, FR Effective date: 20220613 Owner name: UNIVERSITE CLAUDE BERNARD LYON 1, FR Effective date: 20220613 Owner name: ECOLE NORMALE SUPERIEURE DE LYON, FR Effective date: 20220613 Owner name: UNIVERSITE DE ROUEN-NORMANDIE, FR Effective date: 20220613 Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA, FR Effective date: 20220613 Owner name: UNIVERSITE DE REIMS CHAMPAGNE-ARDENNE, FR Effective date: 20220613 |
|
| PLFP | Fee payment |
Year of fee payment: 4 |
|
| PLFP | Fee payment |
Year of fee payment: 5 |